Apellis Pharmaceuticals Inc (APLS)
43.22
+1.91
(+4.62%)
USD |
NASDAQ |
May 20, 16:00
43.22
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Cash from Investing (TTM): -0.708M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.708M |
December 31, 2023 | -0.674M |
September 30, 2023 | 123.45M |
June 30, 2023 | 248.28M |
March 31, 2023 | 331.58M |
December 31, 2022 | 59.89M |
September 30, 2022 | 20.74M |
June 30, 2022 | 75.61M |
March 31, 2022 | 122.43M |
December 31, 2021 | 247.62M |
September 30, 2021 | 162.54M |
Date | Value |
---|---|
June 30, 2021 | 181.66M |
March 31, 2021 | -235.90M |
December 31, 2020 | -316.99M |
September 30, 2020 | -317.05M |
June 30, 2020 | -516.29M |
March 31, 2020 | -228.67M |
December 31, 2019 | -1.693M |
September 30, 2019 | -1.538M |
June 30, 2019 | -1.067M |
March 31, 2019 | -0.875M |
December 31, 2018 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-516.29M
Minimum
Jun 2020
331.58M
Maximum
Mar 2023
-2.338M
Average
10.04M
Median
Cash from Investing (TTM) Benchmarks
Inspire Medical Systems Inc | -310.60M |
Sarepta Therapeutics Inc | 40.50M |
Blueprint Medicines Corp | 178.38M |
Alnylam Pharmaceuticals Inc | -327.75M |
Cytokinetics Inc | 106.40M |